@Steini
Because of your emotional state I think you are underestimating how destructive this biotech winter has been for companies to survive and raise cash. I give you DXB as an example, diluted to buggery to raise cash in a phase 3 trial!!! should I give you more?
OPT
PAR
MAP
The list goes on and on.
I give him the benefit of the doubt that if he had the opportunity he would have done anything to support a raise at a higher price. You don't.
Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-30
Add to My Watchlist
What is My Watchlist?
